Search
C4 Therapeutics Inc
CCCCAdd to Watchlist
3.100USD
+0.150+5.08%
Close 11-06 16:00（ET）
381.39MMarket Cap
LossP/E TTM
After-hours 16:12 (ET)3.060USD-0.025-0.81%
After-hours 16:12 (ET)C4 Therapeutics Inc (CCCC) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to C4 Therapeutics Inc in the past month.
Buy
2 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
12.625USD+274.63%
CCCC Analyst Recommendation Trends
In the current month, CCCC has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CCCC average Analyst price target in the last month is 12.625.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
3
3
3
3
5
5
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
8
8
8
8
CCCC Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CCCC EPS is projected to reach -0.272 in FY2026Q4, following reported EPS of -0.161 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.37
-0.23
-0.20
-0.27
-0.25
Actual
-0.20
-0.18
-0.16
--
--
Surprise
+46.42%
+20.12%
+18.34%
--
--
FAQs
What is C4 Therapeutics Inc's expected revenue for the next quarter?
C4 Therapeutics Inc's expected revenue is 4.93M.
What is C4 Therapeutics Inc's price target?
Analysts forecast that C4 Therapeutics Inc's price target is USD 12.62, with the highest forecast at USD 30.00 and the lowest forecast at USD 7.00.
How have C4 Therapeutics IncCCCC's recent earnings per share performed?
The market expectation was USD -0.16, while C4 Therapeutics IncCCCC's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for C4 Therapeutics Inc?
Based on the ratings of C4 Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.